Epzicom/HLA B*5701

This case study highlights GSK's Epzicom and how, in some patients, it induced hypersensitivity which in turn contributed to a loss in market share. GSK initiated a hands-on study which showed that a diagnostic could be used to prevent the side effect of the drug. Alongside this, it prepared a major marketing campaign in the US to encourage adoption. This led to increased test demand and restored Epzicom's revenue growth. It will help you understand:
  • How GlaxoSmithKline (GSK) drugs containing abacavir (ABC) were discovered to induce hypersensitivity in a small number of patients
  • How the hypersensitivity scare meant that Gilead’s Truvada was able to capture a bigger share of the market
  • How hands-on use studies, to demonstrate unequivocally the role of the test in eliminating the abacavir hypersensitivity problem, helped to restore Epzicom's revenue growth
Download this case study to learn more.
Existing Users Log In